52 results
8-K
EX-99.2
LYEL
Lyell Immunopharma, Inc.
26 Jun 24
Regulation FD Disclosure
8:32am
, and no representation is made as to their safety or effectiveness for the purposes for which they are being investigated. 2 ©2024 Lyell Immunopharma, Inc.
LYL797 … TNBC line of therapy (N~15) RP2D ROR1 positive tumors Dose Level 3 NSCLC Study Objectives (N~15) Safety and tolerability Dose Level 2 Objective response
8-K
EX-99.1
LYEL
Lyell Immunopharma, Inc.
26 Jun 24
Regulation FD Disclosure
8:32am
that CAR T cells enhanced with anti-exhaustion technology can both expand and infiltrate into solid tumors
No significant safety signal related … , 150 x 106 cells and 300 x 106 cells. The efficacy evaluable subset includes 16 patients, and the safety evaluable subset includes 18 patients
8-K
LYEL
Lyell Immunopharma, Inc.
26 Jun 24
Regulation FD Disclosure
8:32am
: 50 x 106 cells, 100 x 106 cells, 150 x 106 cells and 300 x 106 cells. There were 16 efficacy evaluable patients, and 18 safety evaluable patients
424B5
LYEL
Lyell Immunopharma, Inc.
6 May 24
Prospectus supplement for primary offering
8:12am
research activities for LYL797, LYL845, LYL119 or any other product candidates we may develop;
the characteristics, safety, efficacy and therapeutic … the timing thereof;
the ability of our clinical trials to sufficiently demonstrate the safety and efficacy of LYL797, LYL845, LYL119 or any other product
S-3
aqjysg 3plcisxy1sk
28 Feb 24
Shelf registration
7:49pm
8-K
EX-99.1
0xmdocixpm
11 Sep 23
Regulation FD Disclosure
9:16am
8-K
EX-10.1
hzs00isezy1a2w
16 Dec 22
Lyell Immunopharma Appoints Lynn Seely, MD as President and Chief Executive Officer
4:02pm
8-K
EX-99.1
dqqpxp
8 Nov 22
Lyell Immunopharma Reports Recent Business Highlights and Third Quarter Financial Results
4:07pm
8-K
hlbvscwc
24 Oct 22
Termination of a Material Definitive Agreement
5:20pm
8-K
EX-99.1
zg27r
6 Oct 22
Regulation FD Disclosure
4:37pm
S-3ASR
fl07x5
4 Aug 22
Automatic shelf registration
5:29pm